Amsterdam UMC has reported the successful conclusion of what it describes as the world’s first Phase 3 trial of an in vivo CRISPR-based therapy, bringing CRISPR gene editing closer to broader clinical reality. The program was developed in collaboration with multiple international hospitals, with results marking a key regulatory-grade benchmark for in vivo delivery. The study’s Phase 3 completion shifts in vivo CRISPR from proof-of-concept into late-stage validation—an inflection point for assessing durability, efficacy, and safety at the scale required for potential registration. The development underscores continuing progress in overcoming delivery and dosing constraints that have historically limited in vivo genome editing. For biotech stakeholders, the trial outcome is a signal that advanced editing platforms are moving into standard clinical timelines and endpoints rather than remaining confined to early-phase studies.